UBS Group
RNAZ icon

UBS Group’s TransCode Therapeutics RNAZ Stock Holding History

UBS Group’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Sell
2,888
-5,407
-65% -$36.8K ﹤0.01% 8223
2026
Q1 		$71.4K Buy
8,295
+5,331
+180% +$49.7K ﹤0.01% 7173
2025
Q4 		$20.2K Buy
+2,964
New +$30.4K ﹤0.01% 7766
2025
Q3 		– Sell
-1,432
Closed -$11.2K – 10831
2025
Q2 		$11.2K Sell
1,432
-7,994
-85% -$74K ﹤0.01% 8797
2025
Q1 		$131K Buy
9,426
+9,116
+2,941% +$1.17M ﹤0.01% 6836
2024
Q4 		$29.2K Buy
+310
New +$115K ﹤0.01% 7624
2024
Q3 		– Sell
-81
Closed -$75.3K – 9980
2024
Q2 		$75.3K Buy
+81
New +$72.1K ﹤0.01% 6375
2024
Q1 		– Hold
0
– -$1.3K – 9913
2023
Q4 		– Sell
-4
Closed -$45K – 8347
2023
Q3 		$73.7K Buy
+4
New +$251K ﹤0.01% 6043
2023
Q1 		– Hold
0
– -$777 – 10257
2022
Q4 		– Hold
0
– – – 10073
2022
Q2 		– Hold
0
– -$11K – 10839
2022
Q1 		– Hold
0
– – – 8316
2021
Q4 		– Hold
0
– – – 8470
2021
Q3 		– Hold
0
– – – 7428

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's RNAZ Position: Q2 2026 in Review

UBS Group reduced its TransCode Therapeutics (RNAZ) stake by 65% in Q2 2026, selling an estimated $36.8K and leaving 2,888 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8223.

UBS Group first reported a position in RNAZ in Q3 2023 and has held it in 8 quarters since. The position peaked at $131K in Q1 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • UBS Group held 2,888 shares of TransCode Therapeutics worth $17.9K as of Q2 2026.
  • UBS Group sold 5,407 TransCode Therapeutics shares in Q2 2026, an estimated $36.8K.
  • TransCode Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8223 holding.
  • UBS Group first reported a position in TransCode Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • UBS Group's TransCode Therapeutics position peaked at $131K in Q1 2025.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.